SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Abiomed Inc. – ‘8-K’ for 6/17/22

On:  Tuesday, 6/21/22, at 7:12am ET   ·   For:  6/17/22   ·   Accession #:  950170-22-11837   ·   File #:  1-09585

Previous ‘8-K’:  ‘8-K’ on / for 4/28/22   ·   Next:  ‘8-K’ on / for 8/4/22   ·   Latest:  ‘8-K’ on / for 12/22/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/21/22  Abiomed Inc.                      8-K:8       6/17/22   10:166K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 5: R1          Document and Entity Information                     HTML     46K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- abmd-20220617_htm                   XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.LAB  XBRL Labels -- abmd-20220617_lab                     XML     40K 
 4: EX-101.PRE  XBRL Presentations -- abmd-20220617_pre              XML     33K 
 2: EX-101.SCH  XBRL Schema -- abmd-20220617                         XSD     11K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
10: ZIP         XBRL Zipped Folder -- 0000950170-22-011837-xbrl      Zip     12K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C:  C: 
  8-K  
 i 0000815094 i false00008150942022-06-172022-06-17

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i June 17, 2022

 

img17694047_0.jpg 

 i ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 i Delaware

 i 001-09585

 i 04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 i 22 Cherry Hill Drive
 i Danvers,  i Massachusetts  i 01923

(Address of Principal Executive Offices, including Zip Code)

( i 978)  i 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

 i Common Stock, $0.01 par value

 i ABMD

 i The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

Item 8.01 Other Events.

 

In August 2019, the Company announced that its Board of Directors had authorized the repurchase of up to $200 million of the Company’s common stock. Under this stock repurchase program (“the Program”), the Company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Securities Exchange Act of 1934. The Program has no expiration date and may be suspended for periods or discontinued at any time. The Company most recently repurchased shares of its common stock pursuant to a 10b5-1 plan which expired on June 30, 2020. Effective June 17, 2022, the Company entered into a new 10b5-1 plan to continue repurchases of the Company’s common stock under the Program.

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

/s/ Marc A. Began

 

 

 

 

 

Marc A. Began

Vice President, General Counsel and Secretary

Date: June 21, 2022

 

 

 

 

 

 

 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:6/21/22
For Period end:6/17/22
6/30/2010-Q,  DEF 14A,  DEFA14A
 List all Filings 
Top
Filing Submission 0000950170-22-011837   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 3:33:12.1pm ET